Ultragenyx Pharmaceutical to Sell FDA Priority Review Voucher for $203 Million

Ultragenyx Pharmaceutical (RARE) sold a priority review voucher for $203M, received after FDA approval of its rare disease therapy, Fayuvi. The agreement was announced Wednesday.

Ultragenyx (RARE) will sell a Rare Pediatric Disease Priority Review Voucher for $203M, received after FDA approval of FAYUVI. The deal, advised by Jefferies, aims to fund rare disease therapies and improve profitability. Shares fell 1.07% to $14.76 in early trading.

Ultragenyx sold a priority review voucher for rare pediatric diseases to an undisclosed buyer for $203 million. The voucher, granted by the FDA, can expedite the review of a future drug application. Ultragenyx's stock has declined 35.13% year-to-date.

Ultragenyx Pharmaceutical (RARE) sold a Rare Pediatric Disease Priority Review Voucher for $203M. The voucher was received after FDA approval of FAYUVI, a treatment for Sanfilippo syndrome Type A. This is Ultragenyx's second such sale in a week. The deal is subject to regulatory approval. Jefferies LLC and Gibson Dunn are advisors.

Ultragenyx Pharmaceutical Inc. (RARE) agreed to sell a Rare Pediatric Disease Priority Review Voucher for $203M, pending regulatory approval. The deal aligns with the company's strategy to monetize PRVs to support operations and profitability, according to AI Analyst.

Ultragenyx Pharmaceutical Inc. (RARE) announced a $203 million deal to sell a Rare Pediatric Disease Priority Review Voucher (PRV). This is the company's second PRV sale in a week, with proceeds aimed at funding innovative treatments and supporting profitability. The transaction is subject to customary closing conditions, including antitrust review. Jefferies LLC and Gibson, Dunn and Crutcher LLP are advising Ultragenyx on the deal.